Goldman Sachs Group Inc Vanda Pharmaceuticals Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 760,358 shares of VNDA stock, worth $3.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
760,358
Previous 356,546 113.26%
Holding current value
$3.63 Million
Previous $2.01 Million 77.06%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$4.61 - $6.34 $1.86 Million - $2.56 Million
403,812 Added 113.26%
760,358 $3.57 Million
Q2 2024

Aug 13, 2024
SELL
$3.91 - $6.5 $581,960 - $967,453
-148,839 Reduced 29.45%
356,546 $2.01 Million
Q1 2024

May 15, 2024
BUY
$3.47 - $4.61 $153,276 - $203,632
44,172 Added 9.58%
505,385 $2.08 Million
Q4 2023

Feb 13, 2024
SELL
$3.38 - $4.58 $4.09 Million - $5.55 Million
-1,211,363 Reduced 72.42%
461,213 $1.95 Million
Q3 2023

May 14, 2024
BUY
$4.28 - $6.57 $5.18 Million - $7.96 Million
1,211,363 Added 262.65%
1,672,576 $7.23 Million
Q3 2023

Nov 14, 2023
SELL
$4.28 - $6.57 $1.84 Million - $2.83 Million
-430,915 Reduced 20.49%
1,672,576 $7.23 Million
Q2 2023

May 14, 2024
BUY
$5.9 - $6.95 $2.67 Million - $3.15 Million
452,554 Added 27.41%
2,103,491 $13.9 Million
Q2 2023

Aug 14, 2023
BUY
$5.9 - $6.95 $2.67 Million - $3.15 Million
452,554 Added 27.41%
2,103,491 $13.9 Million
Q1 2023

May 14, 2024
BUY
$6.18 - $7.99 $986,964 - $1.28 Million
159,703 Added 10.71%
1,650,937 $11.2 Million
Q1 2023

May 11, 2023
BUY
$6.18 - $7.99 $986,964 - $1.28 Million
159,703 Added 10.71%
1,650,937 $11.2 Million
Q4 2022

May 14, 2024
SELL
$6.87 - $10.96 $1.47 Million - $2.34 Million
-213,680 Reduced 12.53%
1,491,234 $11 Million
Q4 2022

Feb 13, 2023
SELL
$6.87 - $10.96 $1.47 Million - $2.34 Million
-213,680 Reduced 12.53%
1,491,234 $11 Million
Q3 2022

May 14, 2024
SELL
$9.44 - $11.76 $1.21 Million - $1.5 Million
-127,767 Reduced 6.97%
1,704,914 $16.8 Million
Q3 2022

Nov 10, 2022
SELL
$9.44 - $11.76 $1.21 Million - $1.5 Million
-127,767 Reduced 6.97%
1,704,914 $16.8 Million
Q2 2022

May 14, 2024
BUY
$9.31 - $11.84 $12.8 Million - $16.2 Million
1,371,468 Added 297.36%
1,832,681 $20 Million
Q2 2022

Aug 15, 2022
SELL
$9.31 - $11.84 $445,194 - $566,176
-47,819 Reduced 2.54%
1,832,681 $20 Million
Q1 2022

May 16, 2022
BUY
$10.84 - $16.55 $1.94 Million - $2.97 Million
179,244 Added 10.54%
1,880,500 $21.3 Million
Q4 2021

Feb 14, 2022
BUY
$15.69 - $21.14 $13.9 Million - $18.7 Million
885,431 Added 108.53%
1,701,256 $26.7 Million
Q3 2021

Nov 10, 2021
BUY
$15.35 - $21.27 $12.5 Million - $17.4 Million
815,825 New
815,825 $14 Million

Others Institutions Holding VNDA

# of Institutions
161
Shares Held
45.2M
Call Options Held
165K
Put Options Held
33.6K
View Full List

About Vanda Pharmaceuticals Inc.

VNDA Quotes by TradingView
  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $270M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email